MedTrace Logo

A Drug Utilization Study of Radium-223 in Sweden

NCT02331303 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2018-01-23

No results posted yet for this study

Summary

The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.

Conditions

  • Neoplasms

Interventions

OTHER

Radium-223 dichloride (Xofigo, BAY88-8223)

Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-15
Primary Completion
2017-12-19
Completion
2017-12-19

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02331303 on ClinicalTrials.gov